A Specific CNOT1 Mutation Results in a Novel Syndrome of Pancreatic Agenesis and Holoprosencephaly through Impaired Pancreatic and Neurological Development.

We report a recurrent CNOT1 de novo missense mutation, GenBank: NM_016284.4; c.1603C>T (p.Arg535Cys), resulting in a syndrome of pancreatic agenesis and abnormal forebrain development in three individuals and a similar phenotype in mice. CNOT1 is a transcriptional repressor that has been suggested as being critical for maintaining embryonic stem cells in a pluripotent state. These findings suggest that CNOT1 plays a critical role in pancreatic and neurological development and describe a novel genetic syndrome of pancreatic agenesis and holoprosencephaly.IB is funded by Wellcome (WT206194). ATH and SE are the recipients of a Wellcome Trust Senior Investigator award and ATH is employed as a core member of staff within the NIHR funded Exeter Clinical Research Facility and is an NIHR senior investigator. EDF was a Naomi Berrie Fellow in Diabetes Research during the study. SEF has a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (Grant Number: 105636/Z/14/Z). CCW holds a Wellcome Trust Intermediate Clinical Fellowship (Grant Number: 105914/Z/14/Z). HH is funded by the Research Foundation-Flanders (FWO), the VUB Research Council and Stichting Diabetes Onderzoek Nederland

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer.

Breast cancer is a common disease partially caused by genetic risk factors. Germline pathogenic variants in DNA repair genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 are associated with breast cancer risk. FANCM, which encodes for a DNA translocase, has been proposed as a breast cancer predisposition gene, with greater effects for the ER-negative and triple-negative breast cancer (TNBC) subtypes. We tested the three recurrent protein-truncating variants FANCM:p.Arg658*, p.Gln1701*, and p.Arg1931* for association with breast cancer risk in 67,112 cases, 53,766 controls, and 26,662 carriers of pathogenic variants of BRCA1 or BRCA2. These three variants were also studied functionally by measuring survival and chromosome fragility in FANCM -/- patient-derived immortalized fibroblasts treated with diepoxybutane or olaparib. We observed that FANCM:p.Arg658* was associated with increased risk of ER-negative disease and TNBC (OR = 2.44, P = 0.034 and OR = 3.79; P = 0.009, respectively). In a country-restricted analysis, we confirmed the associations detected for FANCM:p.Arg658* and found that also FANCM:p.Arg1931* was associated with ER-negative breast cancer risk (OR = 1.96; P = 0.006). The functional results indicated that all three variants were deleterious affecting cell survival and chromosome stability with FANCM:p.Arg658* causing more severe phenotypes. In conclusion, we confirmed that the two rare FANCM deleterious variants p.Arg658* and p.Arg1931* are risk factors for ER-negative and TNBC subtypes. Overall our data suggest that the effect of truncating variants on breast cancer risk may depend on their position in the gene. Cell sensitivity to olaparib exposure, identifies a possible therapeutic option to treat FANCM-associated tumors

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

Abstract: Breast cancer is a common disease partially caused by genetic risk factors. Germline pathogenic variants in DNA repair genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 are associated with breast cancer risk. FANCM, which encodes for a DNA translocase, has been proposed as a breast cancer predisposition gene, with greater effects for the ER-negative and triple-negative breast cancer (TNBC) subtypes. We tested the three recurrent protein-truncating variants FANCM:p.Arg658*, p.Gln1701*, and p.Arg1931* for association with breast cancer risk in 67,112 cases, 53,766 controls, and 26,662 carriers of pathogenic variants of BRCA1 or BRCA2. These three variants were also studied functionally by measuring survival and chromosome fragility in FANCM−/− patient-derived immortalized fibroblasts treated with diepoxybutane or olaparib. We observed that FANCM:p.Arg658* was associated with increased risk of ER-negative disease and TNBC (OR = 2.44, P = 0.034 and OR = 3.79; P = 0.009, respectively). In a country-restricted analysis, we confirmed the associations detected for FANCM:p.Arg658* and found that also FANCM:p.Arg1931* was associated with ER-negative breast cancer risk (OR = 1.96; P = 0.006). The functional results indicated that all three variants were deleterious affecting cell survival and chromosome stability with FANCM:p.Arg658* causing more severe phenotypes. In conclusion, we confirmed that the two rare FANCM deleterious variants p.Arg658* and p.Arg1931* are risk factors for ER-negative and TNBC subtypes. Overall our data suggest that the effect of truncating variants on breast cancer risk may depend on their position in the gene. Cell sensitivity to olaparib exposure, identifies a possible therapeutic option to treat FANCM-associated tumors

A von Hamos-type hard X-ray spectrometer at the PETRA III beamline P64

The design and performance of the high-resolution wavelength-dispersive multicrystalvon Hamos-type spectrometer at PETRA III beamline P64 aredescribed. Extended analyzer crystal collection available at the beamline allowscoverage of a broad energy range from 5 keV to 20 keV with an energyresolution of 0.35–1 eV. Particular attention was paid to enabling two-colormeasurements by a combination of two types of analyzer crystals and two twodimensionaldetectors. The performance of the spectrometer is demonstrated byelastic-line and emission-line measurements on various compound

Local electronic and crystal structure of rare-earth cobalt phosphides RCo2P2RCo_{2}P_{2} (R = La, Ce, Pr, Nd, Eu) studied by XAFS and RIXS

A detailed combined study of local electronic and crystal structures was performed for a series of rare-earth cobalt phosphides RCo2P2 (R = La, Ce, Pr, Nd, Eu) with peculiar itinerant magnetic ordering schemes using different methods employing the synchrotron radiation: RIXS, XANES and EXAFS. Europium and cerium are shown to be in the intermediate valence state in all compounds. The correlation between rare-earth valence and the observed changes of magnetic ordering in the systems under investigation is discussed

Metal-Insulator Transition in CuIr2S4: XAS Results on the Electronic Structure

S K and Ir L3 x-ray absorption measurements across the temperature-induced metal (M) to insulator (I) transition in Culr2S4 are presented. Dramatic S K-edge changes reflect the Ir d-electronic state redistribution across this transition. These changes, along with a detailed consideration of the I-phase structure, motivate a model in which the I-phase stabilization involves an interplay of charge and d-orbital orientation ordering along Ir chains, a quadrupling of the Ir-chain repeat unit, and correlated dimer spin-singlet formation

A Specific CNOT1 Mutation Results in a Novel Syndrome of Pancreatic Agenesis and Holoprosencephaly through Impaired Pancreatic and Neurological Development.

We report a recurrent CNOT1 de novo missense mutation, GenBank: NM_016284.4; c.1603C>T (p.Arg535Cys), resulting in a syndrome of pancreatic agenesis and abnormal forebrain development in three individuals and a similar phenotype in mice. CNOT1 is a transcriptional repressor that has been suggested as being critical for maintaining embryonic stem cells in a pluripotent state. These findings suggest that CNOT1 plays a critical role in pancreatic and neurological development and describe a novel genetic syndrome of pancreatic agenesis and holoprosencephaly.IB is funded by Wellcome (WT206194). ATH and SE are the recipients of a Wellcome Trust Senior Investigator award and ATH is employed as a core member of staff within the NIHR funded Exeter Clinical Research Facility and is an NIHR senior investigator. EDF was a Naomi Berrie Fellow in Diabetes Research during the study. SEF has a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (Grant Number: 105636/Z/14/Z). CCW holds a Wellcome Trust Intermediate Clinical Fellowship (Grant Number: 105914/Z/14/Z). HH is funded by the Research Foundation-Flanders (FWO), the VUB Research Council and Stichting Diabetes Onderzoek Nederland

Iridium–Iron Diatomic Active Sites for Efficient Bifunctional Oxygen Electrocatalysis

Diatomic catalysts, particularly those with heteronuclear active sites, have recently attracted considerable attention for their advantages over single-atom catalysts in reactions involving multielectron transfers. Herein, we report bimetallic iridium−iron diatomic catalysts (IrFe−N−C) derived from metal−organic frameworks in a facile wet chemical synthesis followed by postpyrolysis. We use various advanced characterization techniques to comprehensively confirm the atomic dispersion of Ir and Fe on the nitrogen-doped carbon support and the presence of atomic pairs. The asobtained IrFe−N−C shows substantially higher electrocatalytic performance for both oxygen reduction reaction (ORR) and oxygen evolution reaction (OER) when compared to the single-atom counterparts (i.e., Ir−N−C and Fe−N−C), revealing favorable bifunctionality. Consequently, IrFe−N−C is used as an air cathode in zinc− air batteries, which display much better performance than the batteries containing commercial Pt/C + RuO2 benchmark catalysts. Our synchrotron-based X-ray absorption spectroscopy experiments and density functional theory (DFT) calculations suggest that the IrFe dual atoms presumably exist in an IrFeN6 configuration where both Ir and Fe coordinates with four N atoms and two N atoms are shared by the IrN4 and FeN4 moieties. Furthermore, the Fe site contributes mainly to the ORR, while the Ir site plays a more important role in the OER. The dual-atom sites work synergistically, reducing the energy barrier of the rate-determining step and eventually boosting the reversible oxygen electrocatalysis. The IrFe−N−C catalysts hold great potential for use in various electrochemical energy storage and conversion devices.info:eu-repo/semantics/publishedVersio